Maria del Rosario García-Miss

Maria del Rosario García-Miss

Auto-generated profile, based on publicly available information

Maria del Rosario García-Miss

Departamento de Neurociencias, Centro de Investigaciones Regionales "Dr. Hideyo Noguchi", Universidad Autónoma de Yucatán, Avenida Itzáes No. 490×59, Mérida, Yucatán, Mexico 97000

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
IAIngrid Aguilar-Be
Ingrid Aguilar-Be
RZRenata da Silva Zardo
Renata da Silva Zardo
ESEdilma Paraguai de Souza
Edilma Paraguai de Souza
GBGulnara Patricia Borja-Cabrera
Gulnara Patricia Borja-Cabrera
MRMiguel Rosado-Vallado
Miguel Rosado-Vallado
Eric DumonteilEric Dumonteil
Eric Dumonteil
The fucose-mannose ligand (FML) complex ofLeishmania donovaniis a promising vaccine candidate against murine and canine visceral leishmaniasis, and its main component is a 36-kDa nucleoside hydrolase (NH36). In this study, we tested the immune response and protection induced by the purified FML, the recombinant NH36 (rNH36), and NH36 DNA vaccines against the agents of visceral (L. chagasi) and cutaneous (L. mexicana) leishmaniasis in BALB/c mice. Mice developed weak humoral response to the vaccines alone, except for those immunized with FML. However, all three vaccine groups presented elevated immunoglobulin G (IgG), IgG1, and IgG2a levels after infection withL. chagasi, whereas no differences were observed between vaccine and control groups after infection withL. mexicana. A strong intradermal reaction toL. donovaniandL. mexicanaantigens was observed in mice immunized with rNH36 or FML, whereas mice immunized with NH36 DNA only reacted againstL. donovaniantigens. Experimental infection of immunized mice demonstrated that FML and rNH36 induced significant protection againstL. chagasiinfection with reductions in parasite loads of 79%. FML also conferred partial protection againstL. mexicanainfection. The best protection was observed in mice immunized with the VR1012-NH36 DNA vaccine, which induced an 88% reduction inL. chagasiparasite load and a 65% reduction inL. mexicanalesion size. Fluorescence-activated cell sorting analysis indicated the DNA vaccine induced a two- to fivefold increase in gamma interferon-producing CD4+T cells, indicating a Th1-type immune response. Our results showed that the NH36 DNA vaccine induced a strong immunoprotection against visceral and cutaneous leishmaniasis, suggesting that this DNA vaccine represents a very good candidate for use against severalLeishmaniaspecies.

1 June 2007 in Fitoterapia
Verified
Journal Article
Closed access
SPSergio R. Peraza-Sánchez
Sergio R. Peraza-Sánchez
FCF. Cen-Pacheco
F. Cen-Pacheco
ANA. Noh-Chimal
A. Noh-Chimal
FMF. May-Pat
F. May-Pat
PSP. Simá-Polanco
P. Simá-Polanco
MMM. Mut-Martín
M. Mut-Martín

1 May 2010 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
MGMaría del Rosario García-Miss
María del Rosario García-Miss
JPJosé Pérez-Mutul
José Pérez-Mutul
BLBelém López-Canul
Belém López-Canul
FSFrancisco Solís-Rodríguez
Francisco Solís-Rodríguez
LPLuis Puga-Machado
Luis Puga-Machado
GAGloria Arankowsky-Sandoval
Gloria Arankowsky-Sandoval

1 March 1990 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
FAFernando J. Andrade-Narvaez
Fernando J. Andrade-Narvaez
ESEmma Simmonds-Diaz
Emma Simmonds-Diaz
SRSantiago Rico-Aguilar
Santiago Rico-Aguilar
MAManuel Andrade-Narvaez
Manuel Andrade-Narvaez
APAndres Palomo-Cetina
Andres Palomo-Cetina
NANelly Albertos-Alpuche
Nelly Albertos-Alpuche
Cutaneous leishmaniasis in Mexico was first described in 1912. Since then, its existence has been repeatedly confirmed in the forest regions of the peninsula of Yucatan. In order to obtain reliable knowledge about the magnitude of this problem, we questioned and skin-tested a sample of 449 persons randomly selected from men aged 15-45 years. We found a positivity rate of 24 to 90% (mean 43%) in the seven rural health posts studied. Furthermore, 72 patients were examined between January and December 1987 by parasitological investigation (smear, isolation, culture and/or biopsy) and the Montenegro skin test; 56 had acquired the disease in 1987. Based on these data, we found an annual incidence rate of 508 per 100,000 inhabitants. Further long-term studies are indicated to determine the incidence and prevalence rates for this disease in other parts of the country.

17 October 2007 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MGM. R. Gamboa‐León
M. R. Gamboa‐León
IAI. Aranda‐González
I. Aranda‐González
MMM. Mut‐Martín
M. Mut‐Martín
MGM. R. García‐Miss
M. R. García‐Miss
Eric DumonteilEric Dumonteil
Eric Dumonteil

1 November 2005 in Vaccine
Verified
Journal Article
Closed access
MRMiguel Rosado-Vallado
Miguel Rosado-Vallado
MMMirza Mut-Martin
Mirza Mut-Martin
MGMaria del Rosario García-Miss
Maria del Rosario García-Miss
Eric DumonteilEric Dumonteil
Eric Dumonteil